Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium aluminosilicate is a naturally occurring mineral clay composed of flat plates of aluminosilicate separated by calcium ions. It acts as a cation exchange absorbent and is not absorbed through the gastrointestinal tract. Its primary mechanism involves adsorbing toxins (including chemotherapeutic drugs and their metabolites) and inflammatory proteins such as TNF-alpha in the gut. This property helps minimize chemotherapy- or radiation-induced diarrhea and may also be useful for other toxin-mediated diarrheal conditions. Calcium aluminosilicate has been studied in both animal models and human trials for cancer-related diarrhea, including medullary thyroid cancer–related diarrhea and chemotherapy-induced diarrhea. While it failed to show efficacy in one trial for preventing severe chemotherapy-induced diarrhea in colon cancer patients, it was considered safe with some evidence of improved stool quality when used alone or with standard antidiarrheals[1][2]. It is also used in veterinary medicine to adsorb mycotoxins from contaminated feed[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium aluminosilicate.